Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial

Neurol Clin. 2011 Feb;29(1):127-48, viii. doi: 10.1016/j.ncl.2010.10.002.


Drug-induced movement disorders have dramatically declined with the widespread use of second-generation antipsychotics, but remain important in clinical practice and for understanding antipsychotic pharmacology. The diagnosis and management of dystonia, parkinsonism, akathisia, catatonia, neuroleptic malignant syndrome, and tardive dyskinesia are reviewed in relation to the decreased liability of the second-generation antipsychotics contrasted with evidence from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Data from the CATIE trial imply that advantages of second-generation antipsychotics in significantly reducing extrapyramidal side effects compared with haloperidol may be diminished when compared with modest doses of lower-potency first-generation drugs.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antipsychotic Agents / adverse effects*
  • Clinical Trials as Topic*
  • Humans
  • Movement Disorders / classification
  • Movement Disorders / etiology*
  • Schizophrenia / drug therapy*


  • Antipsychotic Agents